Abstract
Interleukin-26 (IL-26) is a member of the IL-10 cytokine family due to sequence homology. IL-26 was discovered, since the gene is strongly overexpressed in T cells which are growth transformed by herpesvirus saimiri. The IL-26 gene maps to human chromosome 12q15 between the genes for two other T-cellular class-II cytokines, namely interferon- λ (lFN-λ) and lL-22. IL-26, IL-22, and IFN-λ are co expressed by activated T cells and, especially, by Th17 cells. IL-26 forms homodimers and adheres to glycosaminoglycans on cell surfaces, presumably due to its positive charge. IL-26 specifically targets the lL-26-specific heterodimeric receptor complex consisting of IL-20R1 and IL-10R2 which is typically expressed on epithelial cells such as colon carcinoma cells or keratinocytes. IL-26 stimulation induces STAT1 and STAT3 phosphorylation, CD54 surface expression, and cytokine secretion as shown for IL-8 and IL-10. IL-26 seems to act as a cell surface-associated and rather proinflammatory T-cell cytokine at the epithelial barrier, possibly linking T-cell response with epithelial functions.
Keywords: AK155, colon carcinoma, ICAM-1, Interleukin-26, IL-26, herpes virus saimiri, STAT, T cell, Th17
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Interleukin-26, a Highly Cationic T-Cell Cytokine Targeting Epithelial Cells
Volume: 11 Issue: 3
Author(s): Oliver Braum, Heide Pirzer and Helmut Fickenscher
Affiliation:
Keywords: AK155, colon carcinoma, ICAM-1, Interleukin-26, IL-26, herpes virus saimiri, STAT, T cell, Th17
Abstract: Interleukin-26 (IL-26) is a member of the IL-10 cytokine family due to sequence homology. IL-26 was discovered, since the gene is strongly overexpressed in T cells which are growth transformed by herpesvirus saimiri. The IL-26 gene maps to human chromosome 12q15 between the genes for two other T-cellular class-II cytokines, namely interferon- λ (lFN-λ) and lL-22. IL-26, IL-22, and IFN-λ are co expressed by activated T cells and, especially, by Th17 cells. IL-26 forms homodimers and adheres to glycosaminoglycans on cell surfaces, presumably due to its positive charge. IL-26 specifically targets the lL-26-specific heterodimeric receptor complex consisting of IL-20R1 and IL-10R2 which is typically expressed on epithelial cells such as colon carcinoma cells or keratinocytes. IL-26 stimulation induces STAT1 and STAT3 phosphorylation, CD54 surface expression, and cytokine secretion as shown for IL-8 and IL-10. IL-26 seems to act as a cell surface-associated and rather proinflammatory T-cell cytokine at the epithelial barrier, possibly linking T-cell response with epithelial functions.
Export Options
About this article
Cite this article as:
Braum Oliver, Pirzer Heide and Fickenscher Helmut, Interleukin-26, a Highly Cationic T-Cell Cytokine Targeting Epithelial Cells, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2012; 11 (3) . https://dx.doi.org/10.2174/1871523011202030221
DOI https://dx.doi.org/10.2174/1871523011202030221 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antifungal Therapy of Aspergillosis of the Central Nervous System and Aspergillus Endophthalmitis
Current Pharmaceutical Design Mechanisms for Targeted Delivery of Nanoparticles in Cancer
Current Pharmaceutical Design Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy Functional Consequences of Immune Cell Adhesion to Endothelial Cells
Current Pharmaceutical Design Epigenetic Alterations of the Wnt/β -Catenin Pathway in Human Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Notch Signaling Pathway in Epithelial-Mesenchymal Transition (EMT) During Development and Tumor Aggressiveness
Current Drug Targets Microarrays and Colon Cancer in the Road for Translational Medicine
Current Bioinformatics Development Course and an Application Strategy for Induced Pluripotent Stem Cells in Regenerative Medicine
Current Stem Cell Research & Therapy Gastrin: An Acid-Releasing, Proliferative and Immunomodulatory Peptide?
Mini-Reviews in Medicinal Chemistry MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design MicroRNA-203: Tumor Suppression and Beyond
MicroRNA Synthesis, Characterization by Means of IR, 1H, 13C - NMR and Biological Investigations on New Diorganotin Carboxylic Acid Derivatives
Letters in Drug Design & Discovery Pleiotropic Effect of Mahanine and Girinimbine Analogs: Anticancer Mechanism and its Therapeutic Versatility
Anti-Cancer Agents in Medicinal Chemistry Enhancing the Cytotoxic Activity of Novel Targeted Therapies – Is There a Role for a Combinatorial Approach?
Current Clinical Pharmacology Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms
Current Pharmaceutical Design From the Sea to Anticancer Therapy
Current Medicinal Chemistry Eliminating Ovarian Cancer Stem Cells: A Potential Therapeutic Target for Ovarian Cancer Chemoresistance
Current Protein & Peptide Science Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Current Medicinal Chemistry In vitro Measurement and In vivo Prediction of Time-Dependent Inhibitory Effects of Three Tyrosine Kinase Inhibitors on CYP3A Activity
Current Drug Metabolism Novel Therapeutic Agents Against Cancer Stem Cells of Chronic Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry